Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EPS (Weighted Average and Diluted) (2019 - 2025)

Ptc Therapeutics has reported EPS (Weighted Average and Diluted) over the past 10 years, most recently at -$1.67 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$1.67 for Q4 2025, down 96.47% from a year ago — trailing twelve months through Dec 2025 was $7.74 (up 263.64% YoY), and the annual figure for FY2025 was $7.78, up 264.48%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.67 at Ptc Therapeutics, down from $0.2 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PTCT hit a ceiling of $10.04 in Q1 2025 and a floor of -$2.66 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.72 (2021), compared with a mean of -$1.03.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 936.67% in 2025, while the deepest fall reached 96.47% in 2025.
  • Ptc Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.02 in 2021, then dropped by 16.83% to -$2.36 in 2022, then increased by 12.71% to -$2.06 in 2023, then soared by 58.74% to -$0.85 in 2024, then plummeted by 96.47% to -$1.67 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$1.67 (Q4 2025), $0.2 (Q3 2025), and -$0.83 (Q2 2025) per Business Quant data.